Vera Therapeutics, Inc.
VERA
$36.70
$0.090.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.11% | 27.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.83% | 12.24% | |||
| Operating Income | -32.83% | -12.24% | |||
| Income Before Tax | -32.86% | -13.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.86% | -13.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.86% | -13.46% | |||
| EBIT | -32.83% | -12.24% | |||
| EBITDA | -32.87% | -12.25% | |||
| EPS Basic | -21.99% | -10.38% | |||
| Normalized Basic EPS | -21.84% | -10.14% | |||
| EPS Diluted | -21.99% | -10.38% | |||
| Normalized Diluted EPS | -21.84% | -10.14% | |||
| Average Basic Shares Outstanding | 8.92% | 2.79% | |||
| Average Diluted Shares Outstanding | 8.92% | 2.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||